Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Deep learning enables rapid identification of potent DDR1 kinase inhibitors.

Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, Terentiev VA, Polykovskiy DA, Kuznetsov MD, Asadulaev A, Volkov Y, Zholus A, Shayakhmetov RR, Zhebrak A, Minaeva LI, Zagribelnyy BA, Lee LH, Soll R, Madge D, Xing L, Guo T, Aspuru-Guzik A.

Nat Biotechnol. 2019 Sep;37(9):1038-1040. doi: 10.1038/s41587-019-0224-x. Epub 2019 Sep 2.

PMID:
31477924
2.

Replicative and radiation-induced aging: a comparison of gene expression profiles.

Aliper AM, Bozdaganyan ME, Orekhov PS, Zhavoronkov A, Osipov AN.

Aging (Albany NY). 2019 Apr 19;11(8):2378-2387. doi: 10.18632/aging.101921.

3.

Blood Biochemistry Analysis to Detect Smoking Status and Quantify Accelerated Aging in Smokers.

Mamoshina P, Kochetov K, Cortese F, Kovalchuk A, Aliper A, Putin E, Scheibye-Knudsen M, Cantor CR, Skjodt NM, Kovalchuk O, Zhavoronkov A.

Sci Rep. 2019 Jan 15;9(1):142. doi: 10.1038/s41598-018-35704-w.

4.

Updated functional segregation of retinal ganglion cell projections in the tectum of a cyprinid fish-further elaboration based on microelectrode recordings.

Aliper AT, Zaichikova AA, Damjanović I, Maximov PV, Kasparson AA, Gačić Z, Maximova EM.

Fish Physiol Biochem. 2019 Apr;45(2):773-792. doi: 10.1007/s10695-018-0603-0. Epub 2019 Jan 5.

PMID:
30612338
5.

Putative targets of direction-selective retinal ganglion cells in the tectum opticum of cyprinid fish.

Damjanović I, Maximov PV, Aliper AT, Zaichikova AA, Gačić Z, Maximova EM.

Brain Res. 2019 Apr 1;1708:20-26. doi: 10.1016/j.brainres.2018.12.006. Epub 2018 Dec 5.

PMID:
30527677
6.

Artificial intelligence for aging and longevity research: Recent advances and perspectives.

Zhavoronkov A, Mamoshina P, Vanhaelen Q, Scheibye-Knudsen M, Moskalev A, Aliper A.

Ageing Res Rev. 2019 Jan;49:49-66. doi: 10.1016/j.arr.2018.11.003. Epub 2018 Nov 22. Review.

7.

Aging and drug discovery.

Bakula D, Aliper AM, Mamoshina P, Petr MA, Teklu A, Baur JA, Campisi J, Ewald CY, Georgievskaya A, Gladyshev VN, Kovalchuk O, Lamming DW, Luijsterburg MS, Martín-Montalvo A, Maudsley S, Mkrtchyan GV, Moskalev A, Olshansky SJ, Ozerov IV, Pickett A, Ristow M, Zhavoronkov A, Scheibye-Knudsen M.

Aging (Albany NY). 2018 Nov 13;10(11):3079-3088. doi: 10.18632/aging.101646.

8.

Entangled Conditional Adversarial Autoencoder for de Novo Drug Discovery.

Polykovskiy D, Zhebrak A, Vetrov D, Ivanenkov Y, Aladinskiy V, Mamoshina P, Bozdaganyan M, Aliper A, Zhavoronkov A, Kadurin A.

Mol Pharm. 2018 Oct 1;15(10):4398-4405. doi: 10.1021/acs.molpharmaceut.8b00839. Epub 2018 Sep 19.

9.

Vive la radiorésistance!: converging research in radiobiology and biogerontology to enhance human radioresistance for deep space exploration and colonization.

Cortese F, Klokov D, Osipov A, Stefaniak J, Moskalev A, Schastnaya J, Cantor C, Aliper A, Mamoshina P, Ushakov I, Sapetsky A, Vanhaelen Q, Alchinova I, Karganov M, Kovalchuk O, Wilkins R, Shtemberg A, Moreels M, Baatout S, Izumchenko E, de Magalhães JP, Artemov AV, Costes SV, Beheshti A, Mao XW, Pecaut MJ, Kaminskiy D, Ozerov IV, Scheibye-Knudsen M, Zhavoronkov A.

Oncotarget. 2018 Feb 12;9(18):14692-14722. doi: 10.18632/oncotarget.24461. eCollection 2018 Mar 6. Review.

10.

Adversarial Threshold Neural Computer for Molecular de Novo Design.

Putin E, Asadulaev A, Vanhaelen Q, Ivanenkov Y, Aladinskaya AV, Aliper A, Zhavoronkov A.

Mol Pharm. 2018 Oct 1;15(10):4386-4397. doi: 10.1021/acs.molpharmaceut.7b01137. Epub 2018 Mar 30.

11.

Use of deep neural network ensembles to identify embryonic-fetal transition markers: repression of COX7A1 in embryonic and cancer cells.

West MD, Labat I, Sternberg H, Larocca D, Nasonkin I, Chapman KB, Singh R, Makarev E, Aliper A, Kazennov A, Alekseenko A, Shuvalov N, Cheskidova E, Alekseev A, Artemov A, Putin E, Mamoshina P, Pryanichnikov N, Larocca J, Copeland K, Izumchenko E, Korzinkin M, Zhavoronkov A.

Oncotarget. 2017 Dec 28;9(8):7796-7811. doi: 10.18632/oncotarget.23748. eCollection 2018 Jan 30.

12.

Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare.

Mamoshina P, Ojomoko L, Yanovich Y, Ostrovski A, Botezatu A, Prikhodko P, Izumchenko E, Aliper A, Romantsov K, Zhebrak A, Ogu IO, Zhavoronkov A.

Oncotarget. 2017 Nov 9;9(5):5665-5690. doi: 10.18632/oncotarget.22345. eCollection 2018 Jan 19.

13.

Population Specific Biomarkers of Human Aging: A Big Data Study Using South Korean, Canadian, and Eastern European Patient Populations.

Mamoshina P, Kochetov K, Putin E, Cortese F, Aliper A, Lee WS, Ahn SM, Uhn L, Skjodt N, Kovalchuk O, Scheibye-Knudsen M, Zhavoronkov A.

J Gerontol A Biol Sci Med Sci. 2018 Oct 8;73(11):1482-1490. doi: 10.1093/gerona/gly005.

14.

Towards natural mimetics of metformin and rapamycin.

Aliper A, Jellen L, Cortese F, Artemov A, Karpinsky-Semper D, Moskalev A, Swick AG, Zhavoronkov A.

Aging (Albany NY). 2017 Nov 15;9(11):2245-2268. doi: 10.18632/aging.101319.

15.

Mathematical Justification of Expression-Based Pathway Activation Scoring (PAS).

Aliper AM, Korzinkin MB, Kuzmina NB, Zenin AA, Venkova LS, Smirnov PY, Zhavoronkov AA, Buzdin AA, Borisov NM.

Methods Mol Biol. 2017;1613:31-51. doi: 10.1007/978-1-4939-7027-8_3.

PMID:
28849557
16.

Data aggregation at the level of molecular pathways improves stability of experimental transcriptomic and proteomic data.

Borisov N, Suntsova M, Sorokin M, Garazha A, Kovalchuk O, Aliper A, Ilnitskaya E, Lezhnina K, Korzinkin M, Tkachev V, Saenko V, Saenko Y, Sokov DG, Gaifullin NM, Kashintsev K, Shirokorad V, Shabalina I, Zhavoronkov A, Mishra B, Cantor CR, Buzdin A.

Cell Cycle. 2017 Oct 2;16(19):1810-1823. doi: 10.1080/15384101.2017.1361068. Epub 2017 Aug 21.

17.

A comparative review of computational methods for pathway perturbation analysis: dynamical and topological perspectives.

Vanhaelen Q, Aliper AM, Zhavoronkov A.

Mol Biosyst. 2017 Aug 22;13(9):1692-1704. doi: 10.1039/c7mb00170c. Review.

PMID:
28714509
18.

druGAN: An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico.

Kadurin A, Nikolenko S, Khrabrov K, Aliper A, Zhavoronkov A.

Mol Pharm. 2017 Sep 5;14(9):3098-3104. doi: 10.1021/acs.molpharmaceut.7b00346. Epub 2017 Aug 4.

PMID:
28703000
19.

An analysis of gene expression data involving examination of signaling pathways activation reveals new insights into the mechanism of action of minoxidil topical foam in men with androgenetic alopecia.

Stamatas GN, Wu J, Pappas A, Mirmirani P, McCormick TS, Cooper KD, Consolo M, Schastnaya J, Ozerov IV, Aliper A, Zhavoronkov A.

Cell Cycle. 2017;16(17):1578-1584. doi: 10.1080/15384101.2017.1327492. Epub 2017 Jun 8.

20.

The cornucopia of meaningful leads: Applying deep adversarial autoencoders for new molecule development in oncology.

Kadurin A, Aliper A, Kazennov A, Mamoshina P, Vanhaelen Q, Khrabrov K, Zhavoronkov A.

Oncotarget. 2017 Feb 14;8(7):10883-10890. doi: 10.18632/oncotarget.14073.

21.

In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development.

Ozerov IV, Lezhnina KV, Izumchenko E, Artemov AV, Medintsev S, Vanhaelen Q, Aliper A, Vijg J, Osipov AN, Labat I, West MD, Buzdin A, Cantor CR, Nikolsky Y, Borisov N, Irincheeva I, Khokhlovich E, Sidransky D, Camargo ML, Zhavoronkov A.

Nat Commun. 2016 Nov 16;7:13427. doi: 10.1038/ncomms13427.

22.

New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration.

Pasteuning-Vuhman S, Boertje-van der Meulen JW, van Putten M, Overzier M, Ten Dijke P, Kiełbasa SM, Arindrarto W, Wolterbeek R, Lezhnina KV, Ozerov IV, Aliper AM, Hoogaars WM, Aartsma-Rus A, Loomans CJ.

FASEB J. 2017 Jan;31(1):238-255. doi: 10.1096/fj.201600675R. Epub 2016 Oct 12.

23.

Design of efficient computational workflows for in silico drug repurposing.

Vanhaelen Q, Mamoshina P, Aliper AM, Artemov A, Lezhnina K, Ozerov I, Labat I, Zhavoronkov A.

Drug Discov Today. 2017 Feb;22(2):210-222. doi: 10.1016/j.drudis.2016.09.019. Epub 2016 Sep 28. Review.

PMID:
27693712
24.

In search for geroprotectors: in silico screening and in vitro validation of signalome-level mimetics of young healthy state.

Aliper A, Belikov AV, Garazha A, Jellen L, Artemov A, Suntsova M, Ivanova A, Venkova L, Borisov N, Buzdin A, Mamoshina P, Putin E, Swick AG, Moskalev A, Zhavoronkov A.

Aging (Albany NY). 2016 Sep 24;8(9):2127-2152. doi: 10.18632/aging.101047.

25.

Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data.

Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A.

Mol Pharm. 2016 Jul 5;13(7):2524-30. doi: 10.1021/acs.molpharmaceut.6b00248. Epub 2016 Jun 8.

26.

Deep biomarkers of human aging: Application of deep neural networks to biomarker development.

Putin E, Mamoshina P, Aliper A, Korzinkin M, Moskalev A, Kolosov A, Ostrovskiy A, Cantor C, Vijg J, Zhavoronkov A.

Aging (Albany NY). 2016 May;8(5):1021-33. doi: 10.18632/aging.100968.

27.

Large-scale profiling of signalling pathways reveals an asthma specific signature in bronchial smooth muscle cells.

Alexandrova E, Nassa G, Corleone G, Buzdin A, Aliper AM, Terekhanova N, Shepelin D, Zhavoronkov A, Tamm M, Milanesi L, Miglino N, Weisz A, Borger P.

Oncotarget. 2016 May 3;7(18):25150-61. doi: 10.18632/oncotarget.7209.

28.

DNA repair in species with extreme lifespan differences.

MacRae SL, Croken MM, Calder RB, Aliper A, Milholland B, White RR, Zhavoronkov A, Gladyshev VN, Seluanov A, Gorbunova V, Zhang ZD, Vijg J.

Aging (Albany NY). 2015 Dec;7(12):1171-84.

29.

Color properties of the motion detectors projecting to the goldfish tectum.

Maximova EM, Maximov PV, Damjanović I, Aliper AT, Kasparson AA, Maximov VV.

J Integr Neurosci. 2015 Dec 18:1550027. [Epub ahead of print]

PMID:
26678819
30.

Molecular pathway activation features linked with transition from normal skin to primary and metastatic melanomas in human.

Shepelin D, Korzinkin M, Vanyushina A, Aliper A, Borisov N, Vasilov R, Zhukov N, Sokov D, Prassolov V, Gaifullin N, Zhavoronkov A, Bhullar B, Buzdin A.

Oncotarget. 2016 Jan 5;7(1):656-70. doi: 10.18632/oncotarget.6394.

31.

Aging Chart: a community resource for rapid exploratory pathway analysis of age-related processes.

Moskalev A, Zhikrivetskaya S, Shaposhnikov M, Dobrovolskaya E, Gurinovich R, Kuryan O, Pashuk A, Jellen LC, Aliper A, Peregudov A, Zhavoronkov A.

Nucleic Acids Res. 2016 Jan 4;44(D1):D894-9. doi: 10.1093/nar/gkv1287. Epub 2015 Nov 23.

32.

Geroprotectors.org: a new, structured and curated database of current therapeutic interventions in aging and age-related disease.

Moskalev A, Chernyagina E, de Magalhães JP, Barardo D, Thoppil H, Shaposhnikov M, Budovsky A, Fraifeld VE, Garazha A, Tsvetkov V, Bronovitsky E, Bogomolov V, Scerbacov A, Kuryan O, Gurinovich R, Jellen LC, Kennedy B, Mamoshina P, Dobrovolskaya E, Aliper A, Kaminsky D, Zhavoronkov A.

Aging (Albany NY). 2015 Sep;7(9):616-28.

33.

A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.

Artemov A, Aliper A, Korzinkin M, Lezhnina K, Jellen L, Zhukov N, Roumiantsev S, Gaifullin N, Zhavoronkov A, Borisov N, Buzdin A.

Oncotarget. 2015 Oct 6;6(30):29347-56. doi: 10.18632/oncotarget.5119.

34.

Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs.

Venkova L, Aliper A, Suntsova M, Kholodenko R, Shepelin D, Borisov N, Malakhova G, Vasilov R, Roumiantsev S, Zhavoronkov A, Buzdin A.

Oncotarget. 2015 Sep 29;6(29):27227-38. doi: 10.18632/oncotarget.4507.

35.

[Stimulation of proliferation by carnosine: cellular and transcriptome approaches].

Vishniakova KhS, Babizhaev MA, Aliper AM, Buzdin AA, Kudriavtseva AV, Egorov EE.

Mol Biol (Mosk). 2014 Sep-Oct;48(5):824-33. Russian.

36.

Screening and personalizing nootropic drugs and cognitive modulator regimens in silico.

Jellen LC, Aliper A, Buzdin A, Zhavoronkov A.

Front Syst Neurosci. 2015 Feb 6;9:4. doi: 10.3389/fnsys.2015.00004. eCollection 2015.

37.

Opposing motion inhibits responses of direction-selective ganglion cells in the fish retina.

Damjanović I, Maximova E, Aliper A, Maximov P, Maximov V.

J Integr Neurosci. 2015 Mar;14(1):53-72. doi: 10.1142/S0219635215500077. Epub 2015 Jan 21.

PMID:
25608593
38.

Signaling pathway activation drift during aging: Hutchinson-Gilford Progeria Syndrome fibroblasts are comparable to normal middle-age and old-age cells.

Aliper AM, Csoka AB, Buzdin A, Jetka T, Roumiantsev S, Moskalev A, Zhavoronkov A.

Aging (Albany NY). 2015 Jan;7(1):26-37.

39.

Exhaustive data mining comparison of the effects of low doses of ionizing radiation, formaldehyde and dioxins.

Moskalev A, Shaposhnikov M, Plyusnina E, Plyusnin S, Shostal O, Aliper A, Zhavoronkov A.

BMC Genomics. 2014;15 Suppl 12:S5. doi: 10.1186/1471-2164-15-S12-S5. Epub 2014 Dec 19.

40.

Color properties of the motion detectors projecting to the goldfish tectum: II. Selective stimulation of different chromatic types of cones.

Maximov V, Maximova E, Damjanović I, Aliper A, Maximov P.

J Integr Neurosci. 2015 Mar;14(1):31-52. doi: 10.1142/S0219635215500053. Epub 2015 Jan 2.

PMID:
25553912
41.

Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients.

Zhu Q, Izumchenko E, Aliper AM, Makarev E, Paz K, Buzdin AA, Zhavoronkov AA, Sidransky D.

Hum Genome Var. 2015 Apr 2;2:15009. doi: 10.1038/hgv.2015.9. eCollection 2015.

42.

Pathway activation profiling reveals new insights into age-related macular degeneration and provides avenues for therapeutic interventions.

Makarev E, Cantor C, Zhavoronkov A, Buzdin A, Aliper A, Csoka AB.

Aging (Albany NY). 2014 Dec;6(12):1064-75.

43.

Signaling pathways activation profiles make better markers of cancer than expression of individual genes.

Borisov NM, Terekhanova NV, Aliper AM, Venkova LS, Smirnov PY, Roumiantsev S, Korzinkin MB, Zhavoronkov AA, Buzdin AA.

Oncotarget. 2014 Oct 30;5(20):10198-205.

44.

Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways.

Lezhnina K, Kovalchuk O, Zhavoronkov AA, Korzinkin MB, Zabolotneva AA, Shegay PV, Sokov DG, Gaifullin NM, Rusakov IG, Aliper AM, Roumiantsev SA, Alekseev BY, Borisov NM, Buzdin AA.

Oncotarget. 2014 Oct 15;5(19):9022-32.

45.

Interactome analysis of myeloid-derived suppressor cells in murine models of colon and breast cancer.

Aliper AM, Frieden-Korovkina VP, Buzdin A, Roumiantsev SA, Zhavoronkov A.

Oncotarget. 2014 Nov 30;5(22):11345-53.

46.

Molecular aspects of development and regulation of endometriosis.

Aznaurova YB, Zhumataev MB, Roberts TK, Aliper AM, Zhavoronkov AA.

Reprod Biol Endocrinol. 2014 Jun 13;12:50. doi: 10.1186/1477-7827-12-50. Review.

47.

Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling.

Spirin PV, Lebedev TD, Orlova NN, Gornostaeva AS, Prokofjeva MM, Nikitenko NA, Dmitriev SE, Buzdin AA, Borisov NM, Aliper AM, Garazha AV, Rubtsov PM, Stocking C, Prassolov VS.

Leukemia. 2014 Nov;28(11):2222-8. doi: 10.1038/leu.2014.130. Epub 2014 Apr 14.

PMID:
24727677
48.

A role for G-CSF and GM-CSF in nonmyeloid cancers.

Aliper AM, Frieden-Korovkina VP, Buzdin A, Roumiantsev SA, Zhavoronkov A.

Cancer Med. 2014 Aug;3(4):737-46. doi: 10.1002/cam4.239. Epub 2014 Apr 2. Review.

49.

Genetics and epigenetics of aging and longevity.

Moskalev AA, Aliper AM, Smit-McBride Z, Buzdin A, Zhavoronkov A.

Cell Cycle. 2014;13(7):1063-77. doi: 10.4161/cc.28433. Epub 2014 Mar 6. Review.

50.

The OncoFinder algorithm for minimizing the errors introduced by the high-throughput methods of transcriptome analysis.

Buzdin AA, Zhavoronkov AA, Korzinkin MB, Roumiantsev SA, Aliper AM, Venkova LS, Smirnov PY, Borisov NM.

Front Mol Biosci. 2014 Aug 26;1:8. doi: 10.3389/fmolb.2014.00008. eCollection 2014.

Supplemental Content

Loading ...
Support Center